JP2014240408A5 - - Google Patents

Download PDF

Info

Publication number
JP2014240408A5
JP2014240408A5 JP2014158170A JP2014158170A JP2014240408A5 JP 2014240408 A5 JP2014240408 A5 JP 2014240408A5 JP 2014158170 A JP2014158170 A JP 2014158170A JP 2014158170 A JP2014158170 A JP 2014158170A JP 2014240408 A5 JP2014240408 A5 JP 2014240408A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
eosinophilic
prednisone
treatment
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014158170A
Other languages
English (en)
Japanese (ja)
Other versions
JP6069267B2 (ja
JP2014240408A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2014240408A publication Critical patent/JP2014240408A/ja
Publication of JP2014240408A5 publication Critical patent/JP2014240408A5/ja
Application granted granted Critical
Publication of JP6069267B2 publication Critical patent/JP6069267B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014158170A 2008-03-28 2014-08-01 処置方法 Active JP6069267B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4036308P 2008-03-28 2008-03-28
US61/040,363 2008-03-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2011502090A Division JP5917143B2 (ja) 2008-03-28 2009-03-27 処置方法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016214438A Division JP6457463B2 (ja) 2008-03-28 2016-11-01 処置方法

Publications (3)

Publication Number Publication Date
JP2014240408A JP2014240408A (ja) 2014-12-25
JP2014240408A5 true JP2014240408A5 (enExample) 2016-02-18
JP6069267B2 JP6069267B2 (ja) 2017-02-01

Family

ID=41114741

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2011502090A Active JP5917143B2 (ja) 2008-03-28 2009-03-27 処置方法
JP2014158170A Active JP6069267B2 (ja) 2008-03-28 2014-08-01 処置方法
JP2016214438A Active JP6457463B2 (ja) 2008-03-28 2016-11-01 処置方法
JP2018238018A Pending JP2019065029A (ja) 2008-03-28 2018-12-20 処置方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2011502090A Active JP5917143B2 (ja) 2008-03-28 2009-03-27 処置方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016214438A Active JP6457463B2 (ja) 2008-03-28 2016-11-01 処置方法
JP2018238018A Pending JP2019065029A (ja) 2008-03-28 2018-12-20 処置方法

Country Status (14)

Country Link
US (3) US9834600B2 (enExample)
EP (1) EP2274009B1 (enExample)
JP (4) JP5917143B2 (enExample)
KR (1) KR20100134702A (enExample)
CN (1) CN102026660A (enExample)
AU (1) AU2009228163B2 (enExample)
BR (1) BRPI0910854A2 (enExample)
CA (1) CA2719786A1 (enExample)
EA (1) EA201071137A1 (enExample)
ES (1) ES2441945T3 (enExample)
IL (1) IL208354A0 (enExample)
MX (1) MX2010010667A (enExample)
WO (1) WO2009120927A2 (enExample)
ZA (1) ZA201006648B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010521496A (ja) 2007-03-14 2010-06-24 ノップ ニューロサイエンシーズ、インク. キラル精製置換ベンゾチアゾールジアミンの合成
AU2009228163B2 (en) 2008-03-28 2012-08-30 Glaxosmithkline Llc Methods of treatment
JP2012500283A (ja) 2008-08-19 2012-01-05 ノップ ニューロサイエンシーズ、インク. (r)−プラミペキソールを使用した組成物並びにその方法
CA2807552A1 (en) 2010-08-06 2012-02-09 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
PL3590949T3 (pl) 2010-10-01 2022-08-29 Modernatx, Inc. Kwasy rybonukleinowe zawierające n1-metylo-pseudouracyle i ich zastosowania
DE12722942T1 (de) 2011-03-31 2021-09-30 Modernatx, Inc. Freisetzung und formulierung von manipulierten nukleinsäuren
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
RS62993B1 (sr) 2011-10-03 2022-03-31 Modernatx Inc Modifikovani nukleozidi, nukleotidi, i nukleinske kiseline, i njihove upotrebe
PT2791160T (pt) 2011-12-16 2022-07-04 Modernatx Inc Composições arnm modificado
US9512096B2 (en) 2011-12-22 2016-12-06 Knopp Biosciences, LLP Synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
US10501512B2 (en) 2012-04-02 2019-12-10 Modernatx, Inc. Modified polynucleotides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
AU2013243955B2 (en) 2012-04-02 2018-02-22 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
CA2892529C (en) 2012-11-26 2023-04-25 Moderna Therapeutics, Inc. Terminally modified rna
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
HUE054185T2 (hu) 2013-07-12 2021-08-30 Knopp Biosciences Llc Eozinofilek és/vagy bazofilek megemelkedett szintjének kezelése
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
WO2015023786A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
DK3033081T3 (da) 2013-08-13 2021-05-31 Knopp Biosciences Llc Sammensætninger og fremgangsmåder til behandling af kronisk urticaria
EP3052106A4 (en) 2013-09-30 2017-07-19 ModernaTX, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
PL3191513T3 (pl) * 2014-09-08 2021-02-08 Cephalon, Inc. Zastosowanie reslizumabu do leczenia astmy eozynofilowej od umiarkowanej do ciężkiej
CR20180115A (es) 2015-08-24 2018-04-12 Glaxosmithkline Ip No 2 Ltd Composiciones biofarmacéuticas
AR111764A1 (es) 2017-05-26 2019-08-14 Glaxosmithkline Ip Dev Ltd Proteína de unión a antígeno, anticuerpo que la comprende, cadena peptídica comprendida en el anticuerpo y composiciones relacionadas
JP2023538278A (ja) * 2020-08-05 2023-09-07 アレテイア セラピューティクス、インク. 中等度から重度の喘息の治療におけるデクスプラミペキソールの使用

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
US5096704A (en) * 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
ATE98872T1 (de) 1988-11-03 1994-01-15 Schering Corp Antagonist fuer interleukin-5 zur verhuetung oder verminderung von eosinophilie.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0533006A1 (en) * 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimaeric interleukin 5-receptor/immunoglobulin polypeptides
AU676150B2 (en) 1992-01-23 1997-03-06 Merck Patent Gmbh Monomeric and dimeric antibody-fragment fusion proteins
ZA93779B (en) 1992-02-06 1993-08-05 Schering Corp Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5.
JPH06141885A (ja) 1992-11-05 1994-05-24 Chemo Sero Therapeut Res Inst モノクローナル抗体
AU1289795A (en) 1993-11-19 1995-06-06 Baylor College Of Medicine Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
BR9510499B1 (pt) * 1994-12-23 2009-05-05 antagonistas de il-5 recombinantes úteis no tratamento de distúrbios mediados por il-5.
US5693323A (en) * 1994-12-23 1997-12-02 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US7399837B2 (en) * 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) 1994-12-23 1998-07-21 Smithkline Beecham Corporation Method for treatment and diagnosis of IL-5 mediated disorders
US6248723B1 (en) * 1997-06-10 2001-06-19 National Jewish Medical And Research Center Method for treatment of inflammatory disease
KR20070069220A (ko) * 1997-10-22 2007-07-02 젠스 포니카우 진균류에 의한 점막염을 국소 치료하기 위한 항진균제의용도
WO2001012646A1 (en) 1999-08-19 2001-02-22 Smithkline Beecham Corporation Sialoadhesin factor-1 agonist and antagonist antibodies
US20030017169A1 (en) * 2000-12-29 2003-01-23 Sidney Pestka Controlled release systems for polymers
ATE435239T1 (de) * 2002-03-29 2009-07-15 Schering Corp Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
US7339507B1 (en) * 2006-09-13 2008-03-04 Jiun-In Guo Device for video decoding
EP2111237B1 (en) * 2006-12-11 2015-03-18 BRACCO IMAGING S.p.A. Fibrin-binding peptides and conjugates thereof
EP2152310A4 (en) 2007-04-30 2010-05-26 Glaxosmithkline Llc METHODS OF ADMINISTERING ANTI-IL-5 ANTIBODIES
US20090035216A1 (en) * 2007-08-03 2009-02-05 Biomonitor Aps Method for determining in vivo biopharmaceutical concentration or bioavailability
AU2009228163B2 (en) 2008-03-28 2012-08-30 Glaxosmithkline Llc Methods of treatment
US8926631B2 (en) 2010-08-06 2015-01-06 MoMelan Technologies, Inc. Methods for preparing a skin graft without culturing or use of biologics
SG192671A1 (en) 2011-02-09 2013-09-30 Glaxosmithkline Llc Lyophilized formulations

Similar Documents

Publication Publication Date Title
JP2014240408A5 (enExample)
JP2011516422A5 (enExample)
JP2015529225A5 (enExample)
JP2016528247A5 (enExample)
JP2018184417A5 (enExample)
EP2433650A3 (en) Administration of anti-CD3 antibodies in the treatment of autoimmune diseases
JP2016515124A5 (enExample)
JP2013538553A5 (enExample)
JP2015007098A5 (enExample)
JP2013527233A5 (enExample)
JP2018505882A5 (enExample)
SI2625199T1 (en) Procedures for treating psoriasis using IL-17 antagonists
JP2019533646A5 (enExample)
JP2017160178A5 (enExample)
HRP20231015T1 (hr) Upotreba antagonista il-13 u liječenju atopičnog dermatitisa
JP2012046518A5 (enExample)
JP2014530226A5 (enExample)
JP2016536361A5 (enExample)
MY197558A (en) Methods of treating depression using orexin-2 receptor antagonists
GR1007832B (el) Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
JP2015505564A5 (enExample)
JP2016094424A5 (enExample)
CA2939464A1 (en) Use of anti-ccr5 antibodies in graft versus host disease
JP2018529661A5 (enExample)
JP2016512817A5 (enExample)